華邦健康(002004.SZ):獲得對氨基水楊酸腸溶顆粒的藥品註冊批件
格隆匯 2 月 7日丨華邦健康(002004.SZ)公佈,公司全資子公司重慶華邦製藥有限公司(“華邦製藥”)於近日收到國家藥品監督管理局核准簽發的關於對氨基水楊酸腸溶顆粒的《藥品註冊批件》。
對氨基水楊酸為結核病治療藥物。當由於耐藥或耐受性原因,不能以其他方式制定有效的治療方案時,對氨基水楊酸腸溶顆粒可以作為成人或28天及以上兒童患者的耐多藥結核病治療方案的一部分。
此次公司全資子公司華邦製藥為全國首家獲得藥品對氨基水楊酸腸溶顆粒註冊批件的企業,該藥品註冊批件獲批,視同其通過一致性評價,提高了公司產品的市場競爭力,進一步豐富公司產品管線,拓展了公司產品治療領域,對進一步豐富和優化公司產品結構、探索新的營銷模式均有積極意義。隨着該產品市場佔有率的逐步增加,對公司業績將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.